Q3169056 (Q3169056): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Recently, it has been suggested that cannabidiol (CBD), one of the main components of the Cannabis sativa plant, which lacks potential as an abuse drug, could present antidepressant actions in rodents. It should be noted that these studies have been carried out in acute models, and it is necessary to evaluate their antidepressant efficacy in chronic models, which present a higher degree of translationality to the clinic. This project aims to d...) |
||||||||||||||
| Property / summary | |||||||||||||||
Recently, it has been suggested that cannabidiol (CBD), one of the main components of the Cannabis sativa plant, which lacks potential as an abuse drug, could present antidepressant actions in rodents. It should be noted that these studies have been carried out in acute models, and it is necessary to evaluate their antidepressant efficacy in chronic models, which present a higher degree of translationality to the clinic. This project aims to deepen the antidepressant efficacy of CBD, alone or associated with antidepressant drugs such as fluoxetine (ISRS), evaluating its effects on the mild chronic stress model (LST) on rodents. Different formulations (progressive vs immediate release) and administration pathways will be used. In advance, a pharmacokinetic study will be carried out to assess changes in the plasma concentrations of CBD in the different routes of administration, at different times since administration. In addition, changes in gene and protein expression will be evaluated in different key targets in depression such as the adrenal pituitary hypothalamus axis (CRF, POMC, RCG), endogenous cannabinoid system (CB1, CB2, GPR55), immune system (IL-1ß, IL-10) and serotonergic system (5-HTT, 5-HT1A). It will also be assessed whether CBD modifies ethanol consumption in rodents exposed to MECL. The realisation of this project will provide crucial information on the potential therapeutic usefulness of CBD, alone or associated with antidepressant drugs, and identify some of the mechanisms that regulate its antidepressant efficacy. (English) | |||||||||||||||
| Property / summary: Recently, it has been suggested that cannabidiol (CBD), one of the main components of the Cannabis sativa plant, which lacks potential as an abuse drug, could present antidepressant actions in rodents. It should be noted that these studies have been carried out in acute models, and it is necessary to evaluate their antidepressant efficacy in chronic models, which present a higher degree of translationality to the clinic. This project aims to deepen the antidepressant efficacy of CBD, alone or associated with antidepressant drugs such as fluoxetine (ISRS), evaluating its effects on the mild chronic stress model (LST) on rodents. Different formulations (progressive vs immediate release) and administration pathways will be used. In advance, a pharmacokinetic study will be carried out to assess changes in the plasma concentrations of CBD in the different routes of administration, at different times since administration. In addition, changes in gene and protein expression will be evaluated in different key targets in depression such as the adrenal pituitary hypothalamus axis (CRF, POMC, RCG), endogenous cannabinoid system (CB1, CB2, GPR55), immune system (IL-1ß, IL-10) and serotonergic system (5-HTT, 5-HT1A). It will also be assessed whether CBD modifies ethanol consumption in rodents exposed to MECL. The realisation of this project will provide crucial information on the potential therapeutic usefulness of CBD, alone or associated with antidepressant drugs, and identify some of the mechanisms that regulate its antidepressant efficacy. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Recently, it has been suggested that cannabidiol (CBD), one of the main components of the Cannabis sativa plant, which lacks potential as an abuse drug, could present antidepressant actions in rodents. It should be noted that these studies have been carried out in acute models, and it is necessary to evaluate their antidepressant efficacy in chronic models, which present a higher degree of translationality to the clinic. This project aims to deepen the antidepressant efficacy of CBD, alone or associated with antidepressant drugs such as fluoxetine (ISRS), evaluating its effects on the mild chronic stress model (LST) on rodents. Different formulations (progressive vs immediate release) and administration pathways will be used. In advance, a pharmacokinetic study will be carried out to assess changes in the plasma concentrations of CBD in the different routes of administration, at different times since administration. In addition, changes in gene and protein expression will be evaluated in different key targets in depression such as the adrenal pituitary hypothalamus axis (CRF, POMC, RCG), endogenous cannabinoid system (CB1, CB2, GPR55), immune system (IL-1ß, IL-10) and serotonergic system (5-HTT, 5-HT1A). It will also be assessed whether CBD modifies ethanol consumption in rodents exposed to MECL. The realisation of this project will provide crucial information on the potential therapeutic usefulness of CBD, alone or associated with antidepressant drugs, and identify some of the mechanisms that regulate its antidepressant efficacy. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 18:47, 12 October 2021
Project Q3169056 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3169056 in Spain |
Statements
68,500.0 Euro
0 references
137,000.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
UNIVERSIDAD MIGUEL HERNANDEZ
0 references
38°20'37.10"N, 0°29'17.41"W
0 references
03014
0 references
Recientemente, se ha sugerido que el cannabidiol (CBD), uno de los principales componentes de la planta Cannabis sativa, que carece de potencial como droga de abuso, podría presentar acciones antidepresivas en roedores. Cabe destacar que estos estudios se han realizado en modelos agudos, siendo necesario, evaluar su eficacia antidepresiva en modelos crónicos, que presentan un mayor grado de traslacionalidad a la clínica. Este proyecto tiene como objetivo profundizar en la eficacia antidepresiva del CBD, sólo o asociado a fármacos antidepresivos como la fluoxetina (ISRS), evaluando sus efectos en el modelo de estrés crónico leve (ECL) en roedores. Se emplearán diferentes formulaciones (de liberación progresiva vs inmediata) y vías de administración. Previamente, se realizará un estudio farmacocinético que permitirá valorar los cambios en las concentraciones plasmáticas de CBD de las diferentes vías de administración, a distintos tiempos desde su administración. Además, se evaluarán cambios en la expresión génica y proteica en diferentes dianas claves en la depresión como el eje hipotálamo hipófisis adrenal (CRF, POMC, rCG), sistema cannabinoide endógeno (CB1, CB2, GPR55), sistema inmune (IL-1ß, IL-10) y sistema serotoninérgico (5-HTT, 5-HT1A). Asimismo, se evaluará si el CBD modifica el consumo de etanol en roedores expuestos al MECL. La realización de este proyecto permitirá obtener información crucial sobre la potencial utilidad terapéutica del CBD, sólo y/o asociado a fármacos antidepresivos, e identificar algunos de los mecanismos que regulan su eficacia antidepresiva. (Spanish)
0 references
Recently, it has been suggested that cannabidiol (CBD), one of the main components of the Cannabis sativa plant, which lacks potential as an abuse drug, could present antidepressant actions in rodents. It should be noted that these studies have been carried out in acute models, and it is necessary to evaluate their antidepressant efficacy in chronic models, which present a higher degree of translationality to the clinic. This project aims to deepen the antidepressant efficacy of CBD, alone or associated with antidepressant drugs such as fluoxetine (ISRS), evaluating its effects on the mild chronic stress model (LST) on rodents. Different formulations (progressive vs immediate release) and administration pathways will be used. In advance, a pharmacokinetic study will be carried out to assess changes in the plasma concentrations of CBD in the different routes of administration, at different times since administration. In addition, changes in gene and protein expression will be evaluated in different key targets in depression such as the adrenal pituitary hypothalamus axis (CRF, POMC, RCG), endogenous cannabinoid system (CB1, CB2, GPR55), immune system (IL-1ß, IL-10) and serotonergic system (5-HTT, 5-HT1A). It will also be assessed whether CBD modifies ethanol consumption in rodents exposed to MECL. The realisation of this project will provide crucial information on the potential therapeutic usefulness of CBD, alone or associated with antidepressant drugs, and identify some of the mechanisms that regulate its antidepressant efficacy. (English)
12 October 2021
0 references
Alicante/Alacant
0 references
Identifiers
PI18_00576
0 references